Cholesterol efflux capacity, carotid atherosclerosis, and cerebrovascular symptomatology

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 34, Issue 4, 2014, Pages 921-926

  Doonan, R J ^a   Hafiane, A ^a   Lai, C ^b   Veinot, J P ^b   Genest, J ^c   Daskalopoulou, S S ^a,d  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

carotid artery diseases; carotid stenosis

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL; CYCLIC AMP; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MACROGOL; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR PARAMETERS; CAROTID ARTERY OBSTRUCTION; CAROTID ATHEROSCLEROSIS; CAROTID ENDARTERECTOMY; CEREBROVASCULAR DISEASE; CHOLESTEROL EFFLUX CAPACITY; CONTROLLED STUDY; DISEASE ASSOCIATION; EFFUSION; FEMALE; FRAMINGHAM RISK SCORE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MIDDLE AGED; PRIORITY JOURNAL; SYMPTOMATOLOGY;

CAROTID ARTERY DISEASES; CAROTID STENOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BIOLOGICAL MARKERS; CAROTID STENOSIS; CASE-CONTROL STUDIES; CELL LINE; CEREBROVASCULAR DISORDERS; CHI-SQUARE DISTRIBUTION; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; CYCLIC AMP; DISEASE PROGRESSION; FEMALE; HUMANS; LOGISTIC MODELS; MACROPHAGES; MALE; MICE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLAQUE, ATHEROSCLEROTIC; QUEBEC; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84897453756     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.113.302590     Document Type: Article

References (22)

1. Di Angelantonio E, Sarwar N, Perry P et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993-2000.
2. Gordon DJ, Probstfeld JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, Jacobs DR Jr, Bangdiwala S, Tyroler HA. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989;79:8-15.
3. Navab M, Reddy ST, Van Lenten BJ, Fogelman AM. HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms. Nat Rev Cardiol. 2011;8:222-232.
4. Hafane A, Genest J. HDL, Atherosclerosis, and Emerging Therapies. Cholesterol. 2013;2013:891403.
5. Barter PJ, Caulfeld M, Eriksson M, et al; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
6. Schwartz GG, Olsson AG, Abt M, et al; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med. 2012;367:2089-2099.
7. Tall AR. Cholesterol effux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med. 2008;263:256-273.
8. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ. Cholesterol effux capacity, high-density lipopro-tein function, and atherosclerosis. N Engl J Med. 2011;364:127-135.
9. Li XM, Tang WH, Mosior MK, Huang Y, Wu Y, Matter W, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL. Paradoxical association of enhanced cholesterol effux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol. 2013;33:1696-1705.
10. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W Jr, Rosenfeld ME, Schwartz CJ, Wagner WD, Wissler RW. A defnition of advanced types of atherosclerotic lesions and a histological classifcation of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1995;92:1355-1374.
11. Hafane A, Jabor B, Ruel I, Ling J, Genest J. High-density lipoprotein mediated cellular cholesterol effux in acute coronary syndromes. Am J Cardiol. 2014;113:249-255.
12. Khera AV, Rader DJ. Cholesterol effux capacity: full steam ahead or a bump in the road? Arterioscler Thromb Vasc Biol. 2013;33:1449-1451.
13. van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, Brooks-Wilson A, Zwinderman AH, Smit AJ, Smelt AH, Groen AK, Hayden MR, Kastelein JJ. Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol effux: an observational study. Lancet. 2002;359:37-42.
14. Finn AV, Kolodgie FD, Virmani R. Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. Arterioscler Thromb Vasc Biol. 2010;30:177-181
15. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Benefcial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med. 1991;325:445-453
16. MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet. 1991;337:1235-1243.
17. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Stroke Association, American Association of Neuroscience Nurses, American Association of Neurological Surgeons, American College of Radiology, American Society of Neuroradiology, Congress of Neurological Surgeons, Society of Atherosclerosis Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. J Am Coll Cardiol. 2011;57:1002-1044.
18. Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010;153:387-395.
19. Virmani R, Ladich ER, Burke AP, Kolodgie FD. Histopathology of carotid atherosclerotic disease. Neurosurgery. 2006;59(5 suppl 3):S219-S227; discussion S3.
20. Albrecht C, Soumian S, Amey JS, Sardini A, Higgins CF, Davies AH, Gibbs RG. ABCA1 expression in carotid atherosclerotic plaques. Stroke. 2004;35:2801-2806.
21. Liu HF, Cui KF, Wang JP, Zhang M, Guo YP, Li XY, Jiang C. Signifcance of ABCA1 in human carotid atherosclerotic plaques. Exp Ther Med. 2012;4:297-302.
22. de la Llera-Moya M, Drazul-Schrader D, Asztalos BF, Cuchel M, Rader DJ, Rothblat GH. The ability to promote effux via ABCA1 determines the capacity of serum specimens with similar high-density lipoprotein cholesterol to remove cholesterol from macrophages. Arterioscler Thromb Vasc Biol. 2010;30:796-801.